![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Reduction in Annual Medical Costs with Early Treatment of HCV Using Abbvie 3D (AbT-450/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin in the United States
|
|
|
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
SJ Johnson1, JC Samp2, TR Juday2, SE Marx2, H Parisé1, S virabhak1, S Saab3
1Medicus Economics, Milton, 2Global Health Economics and Outcomes Research, Abbvie, Mettawa, 3Pfleger Liver Institute, Los Angeles, United States
![EASL1.gif](../images/042815/042815-10/EASL1.gif)
![EASL2.gif](../images/042815/042815-10/EASL2.gif)
![EASL3.gif](../images/042815/042815-10/EASL3.gif)
![EASL4.gif](../images/042815/042815-10/EASL4.gif)
![EASL5.gif](../images/042815/042815-10/EASL5.gif)
![EASL6.gif](../images/042815/042815-10/EASL6.gif)
![EASL7.gif](../images/042815/042815-10/EASL7.gif)
![EASL8.gif](../images/042815/042815-10/EASL8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|